-
Dutch authorities hand over final building to EMA in Amsterdam
Dutch authorities hand over final building to EMA in Amsterdam
-
Dutch authorities hand over final building to EMA in Amsterdam
Dutch authorities hand over final building to EMA in Amsterdam
The Dutch authorities have handed over to EMA its newly built tailor-made premises, located in the Zuidas area of Amsterdam. Guido Rasi, EMA’s Executive Director, signed the lease agreement and thanked the Dutch authorities for reaching this important milestone on time. EMA staff will gradually move into this building in January.
-
CHMP highlights: November 2019
CHMP highlights: November 2019
-
CHMP highlights: November 2019
CHMP highlights: November 2019
EMA’s human medicines committee (CHMP) recommended seven medicines for approval at its 11-14 November meeting.
-
Shaping regulatory science to 2025
Shaping regulatory science to 2025
-
Shaping regulatory science to 2025
Shaping regulatory science to 2025
EMA is hosting a multi-stakeholder workshop on the human medicine aspects of its draft ‘Regulatory Science Strategy to 2025’ on 18-19 November. Participants will discuss the outcome of EMA’s public consultation on the draft strategy. The workshop can be followed via live broadcast.
-
Nitrosamine impurities: latest information
Nitrosamine impurities: latest information
-
Nitrosamine impurities: latest information
Nitrosamine impurities: latest information
Visit our new webpage on nitrosamine impurities in human medicines for a full, up-to-date overview of EMA’s past and ongoing reviews into this issue. It includes new templates for marketing authorisation holders to report the outcome of the requested risk evaluation and testing, as well as the updated questions-and-answers document with a list of potential sources of nitrosamine contamination. Bookmark the page for quick access to the latest updates.
